Palvella's experienced Board is very committed to the company's success accounting for a significant portion of Palvella’s financing to date. Palvella has also been financed by leading early stage biopharmaceutical venture capital firms with track records of success in the rare disease space. We also enjoy investment support from several life sciences angels, many of whom have been directly involved in the development and commercialization of high impact biopharmaceutical therapies, including therapies for rare diseases. Our investors are long-term oriented and aligned with Palvella’s mission.

 

Founded and led by the former Baxalta Ventures investment team (the corporate venture capital arm of Baxalta), Agent Capital is a biotech venture capital firm focused on investing in novel, differentiated therapeutics that address unmet patient need.  

BioAdvance is a $50M early stage life sciences fund, working with entrepreneurs in the mid-Atlantic region to build strong companies that have the potential to improve human health. BioAdvance portfolio companies have leveraged $2.65 billion in subsequent capital, including proceeds from twelve acquisitions. Eleven products have received FDA approval.